15 April 2026 Sydney, Australia

Nyrada Quarterly Activities Report & Appendix 4C

Highlights:

- Xolatryp Program
  - Human Research Ethics Committee (HREC) approval to conduct Phase IIa clinical trial received.
  - Clinical trial will assess safety and preliminary efficacy of Xolatryp® in heart attack patients undergoing angioplasty with stenting.
  - Patient recruitment to commence in April 2026.
  - Preclinical animal studies initiated to assess efficacy of Xolatryp in oncology indication.
- Finance and Capital
  - Sound financial position with a cash balance of AU$6.74 million at 31 March 2026.
  - R&D tax rebate in amount of AU$2.45 million expected in respect to FY2025.
  - Composition of matter patent published.

Nyrada Inc (ASX:NYR), a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today announces its Quarterly Activities Report and Appendix 4C for the three months ending 31 March 2026.

Xolatryp® Program

Phase IIa Clinical Trial

During the quarter, Nyrada received Human Research Ethics Committee (HREC) approval to conduct its Phase IIa clinical trial to assess the safety and preliminary efficacy of Xolatryp® in heart attack patients undergoing angioplasty with stenting (percutaneous coronary intervention or PCI).

Patient recruitment will commence in April 2026 with initial trial site hospitals sites confirmed.

Although safety is the primary endpoint of this Phase IIa trial, multiple secondary and exploratory efficacy endpoints are also being evaluated, including cardiac function, extent of cardiac injury, biomarkers such as troponin I levels, and the incidence of arrhythmias of interest.

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

As this Phase IIa trial is designed as a randomised, double-blind, placebo-controlled study, efficacy data will not be available until after the completion of the study. The Company will, however, provide periodic updates to the market regarding participant recruitment and Safety Review Committee (SRC) assessments.

Nyrada has also commenced preparation of its Investigational New Drug (IND) application to submit to the US Food and Drug Administration (FDA). This proposed IND will cover Nyrada's myocardial ischemia reperfusion injury program.

Research and Development

During the quarter, Nyrada initiated a preclinical studies to assess the efficacy of Xolatryp across oncology indications, including its potential to provide cardioprotection against anthracycline-induced cardiotoxicity.

Doxorubicin, one of the most widely used anthracycline chemotherapy drugs, is considered a "backbone drug" in oncology given its role in many standard treatment regimens. A well-recognised risk of Doxorubicin use is cardiac damage, particularly at higher cumulative doses, which is why oncologists closely monitor lifetime patient exposure. Scientific literature suggests Xolatryp may offer cardioprotection against Doxorubicin-induced cardiotoxicity.

Nyrada will update the market as material information becomes available.

Patent

Nyrada submitted its composition of matter patent application in September 2024. Subject to grant of the patent, Nyrada will receive 20 years of intellectual property protection from this priority date.

As a general guide, it can take three to four years for a composition of matter patent to be granted following submission. One of the key steps in this process is the publication of the patent, which occurred late in the quarter.

Finance, Capital and Corporate

As at 31 March 2026, Nyrada had a cash position of AU$6.74 million (AU$7.12 million as at 31 December 2025). Total cash operating outflows for the March 2026 quarter were approximately AU$970,000, offset by AU$80,000 interest income received.

During the quarter, AU$0.51 million was received from exercise of options.

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C were approximately AU$219,000 (approximately AU$270,000 for the quarter ending 31 December 2025) and includes Director fees for the Chair and Non-Executive directors (including superannuation) and salary and superannuation for the Managing Director/CEO.

As per prior years, the Company has applied for the Australian Government's R&D Tax incentive for the financial year ended 30 June 2025, estimating a refund of AU$2.45 million. This is an upward revision of the prior advised estimate of AU$2.16 million.

Nyrada has not yet received its R&D tax incentive refund for the period ending 30 June 2025 due to a delay in obtaining its Advanced Overseas Finding, a required approval necessary for claiming research expenditure incurred outside Australia. This has now been received. It is expected the FY25 refund will be received before the end of the 2026 financial year.

About Xolatryp®

Xolatryp, previously called NYR-BI03, is a small molecule therapy that inhibits calcium ion influx via TRPC 3/6/7 channels. By limiting pathological calcium entry, it helps protect mitochondrial function and reduces ischemia reperfusion injury associated with acute myocardial infarction (heart attack).

A Phase I clinical trial assessing the safety, tolerability, and pharmacokinetics has been completed, and a Phase IIa clinical trial focusing on safety and preliminary efficacy will commence in April 2026. This upcoming study will enrol patients who suffer a heart attack and undergo Percutaneous Coronary Intervention (PCI - angioplasty with stenting).

Program Links:

- PROTECT-MI website - https://www.protect-mi.com
- Corporate presentation/about MI - https://bit.ly/4dDWNCz
- Phase IIa factsheet - https://bit.ly/4bcDlKj
- Phase I results - https://bit.ly/3Nt0GzH
- GLP study results - https://bit.ly/4d8VYkX
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg
- Preclinical traumatic brain injury study - https://bit.ly/40fhrRT
- Preclinical stroke study - https://bit.ly/4sygHmH

-ENDS-

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in both cardioprotection and neuroprotection, and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial is soon to commence. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Nyrada Inc.	
ABN	**Quarter ended ("current quarter")**
54 625 401 818	31 March 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(378)	(3,358)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(314)	(951)
	(f) administration and corporate costs	(278)	(1,145)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	80	92
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(890)**	**(5,362)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	(2)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**(2)**

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	8,121
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	506	1,465
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(7)	(412)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**499**	**9,174**

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	7,122	2,931
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(890)	(5,362)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(2)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	499	9,174
4.5	Effect of movement in exchange rates on cash held	4	(6)
4.6	**Cash and cash equivalents at end of period**	**6,735**	**6,735**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,206	2,122
5.2	Call deposits	2,529	5,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**6,735**	**7,122**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	219
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes Director fees for the Chair and Non-Executive directors (including superannuation)and salary and superannuation for the CEO/Managing Director

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(890)
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,735
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	6,735
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**7.6**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:
N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:
N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:
N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

15 April 2026

Date: .....

By the Board

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.